



Representatives from Illumina gather at their booth during ESMO 2024. Photo by Mike Rowland

Highlighting the role of comprehensive genomic profiling in cancer treatment at ESMO 2024

Genomics experts from Italy, Norway, and Wales joined an Illumina-hosted panel on liquid biopsy

AT THE ANNUAL European Society for Medical Oncology (ESMO)¹ congress in Barcelona, Spain, Illumina brought together oncologists, patient advisory groups, clinicians, and researchers to discuss the growing evidence on the benefits of comprehensive genomic profiling (CGP) using liquid biopsy, and how it can help to inform therapy decisions and improve patient care.

This revolutionary technique uses a blood test to detect circulating tumor DNA, which is then sequenced to assess multiple biomarkers in numerous tumor types using a single next-generation sequencing assay. This process is less invasive for patients, requiring a one-time test rather than multiple biopsies, which can add to the patient's discomfort and prolong the wait for a diagnosis.

Illumina hosted a symposium on liquid-biopsy-based

biomarkers during the conference. Professor Umberto Malapelle from the University of Naples highlighted the value of liquid biopsy testing in oncology. Magda Meissner from the QuicDNA project in Wales² offered a clear example of the value of government-funded testing in non-small-cell lung cancer using liquid biopsy CGP.

Åslaug Helland from the IMPRESS Norway project³ spoke about the promise of CGP in the treatment of advanced cancer, and Stephen Rowley shared his experience living with colorectal cancer and why he continues to advocate for patients and their families after finishing treatment. ♦

Watch the video at youtube.com/watch?v=TmRHk5zcl4g

1. [esmo.org](https://www.esmo.org)

2. illumina.com/company/news-center/feature-articles/a-liquid-biopsy-study-offers-new-hope-for-lung-cancer-patients.html

3. impress-norway.no/en/impress-norway-front-page

For Research Use Only. Not for use in diagnostic procedures.

© 2024 Illumina, Inc. All rights reserved. All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.